CRINETICS PHARMACEUTICALS IN
CRNXNASDAQ🏆 #951 by market capEarnings Nov 5US Equity
$84.95▲ $0.00 (+0.00%)
🌙 After hours$84.98▲ 0.03%Regular close · extended-hours price shownTrack CRNX
Get earnings, price moves & breaking news on Telegram
24h▲ 0.0%
7d▲ 0.0%
14d▲ 0.0%
30d▲ 0.1%
ytd▲ 82.5%
1y▲ 95.6%
🏦Market Cap
$8.99B
Small Cap
📈Revenue Growth (YoY)
+2928.4%
High Growth
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
213.8x
Expensive
Otter Score
76
Good
CRINETICS PHARMACEUTICALS IN
CRNXAnalyst Ratings
Price
$84.95
Total
21
Raised
1
Lowered
8
Avg PT
$84.86
H / L
$85 / $84
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
UBS | Downgraded | Buy → Neutral | 2026-07-28 | $85.00 | +0.10% |
TD Cowen | Downgraded | Buy → Hold | 2026-07-08 | — | — |
Evercore ISI Group | Downgraded | Outperform → In Line | 2026-07-08 | — | — |
HC Wainwright & Co. | Downgraded | Buy → Neutral | 2026-07-07 | — | — |
Jones Trading | Downgraded | Buy → Hold | 2026-07-07 | — | — |
Cantor Fitzgerald | Downgraded | Overweight → Neutral | 2026-07-07 | — | — |
Jefferies | Downgraded | Buy → Hold | 2026-07-07 | $85.00 | +0.10% |
Oppenheimer | Downgraded | Outperform → Perform | 2026-07-07 | $84.00 | −1.10% |
Baird | Reiterated | Outperform | 2026-07-07 | — | — |
Citizens | Reiterated | Market Outperform | 2026-06-11 | — | — |
Goldman Sachs | Upgraded | Neutral → Buy | 2026-01-12 | $67.00 | −21.10% |
Morgan Stanley | Reiterated | Overweight | 2026-01-06 | $87.00 | +2.40% |
Leerink Partners | Reiterated | Outperform | 2025-09-29 | $39.00 | −54.10% |
JMP Securities | Reiterated | Market Outperform | 2025-09-26 | $143.00 | +68.30% |
JP Morgan | Reiterated | Overweight | 2025-09-24 | — | — |
Citizens Capital Markets | Reiterated | Market Outperform | 2025-02-28 | — | — |
Citigroup | Reiterated | Buy | 2024-11-14 | — | — |
Piper Sandler | Reiterated | Overweight | 2024-07-02 | $97.00 | +14.20% |
JonesTrading | Reiterated | Buy | 2024-03-20 | — | — |
HC Wainwright& Co. | Reiterated | Buy | 2024-03-19 | — | — |
SVB Leerink | Reiterated | Outperform | 2022-05-26 | — | — |
Institution
UBS
Downgraded · Buy → Neutral · 2026-07-28
$85.00
+0.10%
TD Cowen
Downgraded · Buy → Hold · 2026-07-08
—
—
Evercore ISI Group
Downgraded · Outperform → In Line · 2026-07-08
—
—
HC Wainwright & Co.
Downgraded · Buy → Neutral · 2026-07-07
—
—
Jones Trading
Downgraded · Buy → Hold · 2026-07-07
—
—
Cantor Fitzgerald
Downgraded · Overweight → Neutral · 2026-07-07
—
—
Jefferies
Downgraded · Buy → Hold · 2026-07-07
$85.00
+0.10%
Oppenheimer
Downgraded · Outperform → Perform · 2026-07-07
$84.00
−1.10%
Baird
Reiterated · Outperform · 2026-07-07
—
—
Citizens
Reiterated · Market Outperform · 2026-06-11
—
—
Goldman Sachs
Upgraded · Neutral → Buy · 2026-01-12
$67.00
−21.10%
Morgan Stanley
Reiterated · Overweight · 2026-01-06
$87.00
+2.40%
Leerink Partners
Reiterated · Outperform · 2025-09-29
$39.00
−54.10%
JMP Securities
Reiterated · Market Outperform · 2025-09-26
$143.00
+68.30%
JP Morgan
Reiterated · Overweight · 2025-09-24
—
—
Citizens Capital Markets
Reiterated · Market Outperform · 2025-02-28
—
—
Citigroup
Reiterated · Buy · 2024-11-14
—
—
Piper Sandler
Reiterated · Overweight · 2024-07-02
$97.00
+14.20%
JonesTrading
Reiterated · Buy · 2024-03-20
—
—
HC Wainwright& Co.
Reiterated · Buy · 2024-03-19
—
—
SVB Leerink
Reiterated · Outperform · 2022-05-26
—
—
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space